ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Friday

ALX Oncology (NASDAQ:ALXO) is expected to post its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

ALX Oncology Stock Down 1.2%

Shares of NASDAQ:ALXO opened at $2.42 on Thursday. The stock has a market capitalization of $131.21 million, a P/E ratio of -1.19 and a beta of 0.51. The stock’s 50-day moving average price is $1.67 and its 200-day moving average price is $1.48. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.13. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.66.

Wall Street Analysts Forecast Growth

ALXO has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a report on Wednesday, January 21st. Piper Sandler increased their target price on shares of ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Jefferies Financial Group assumed coverage on ALX Oncology in a report on Thursday, November 13th. They set a “buy” rating and a $4.00 price target on the stock. Finally, Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, ALX Oncology currently has an average rating of “Moderate Buy” and an average target price of $2.50.

Insider Buying and Selling at ALX Oncology

In other news, Director Corey S. Goodman bought 3,184,713 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was purchased at an average price of $1.57 per share, with a total value of $4,999,999.41. Following the transaction, the director owned 8,453,038 shares of the company’s stock, valued at approximately $13,271,269.66. The trade was a 60.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 21.00% of the company’s stock.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. purchased a new position in ALX Oncology during the first quarter valued at $46,000. Bridgeway Capital Management LLC bought a new position in shares of ALX Oncology during the third quarter valued at $66,000. AQR Capital Management LLC increased its holdings in shares of ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after acquiring an additional 77,065 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ALX Oncology in the 2nd quarter worth about $84,000. Finally, State Street Corp boosted its stake in ALX Oncology by 11.0% in the 4th quarter. State Street Corp now owns 124,228 shares of the company’s stock worth $140,000 after purchasing an additional 12,300 shares in the last quarter. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.